The PML-RARa hybrid protein generated by the t(15;17) translocation in acute promyelocytic leukemia (APL) is thought to play a central role in the oncogenic process. However, analysis of the oncogenic activity of the fusion protein in tissue culture assays or in mice has been hampered by its apparent toxicity in multiple murine cells. To circumvent this problem, we generated an inducible line of transgenic mice, MT135, in which the expression of PML-RARa is driven by the metallothionein promoter. After 5 days zinc stimulation, 27 out of 54 mice developed hepatic preneoplasia and neoplasia including foci of basophilic hepatocytes, dysplasia and carcinoma with a signi®cantly higher incidence of lesions in females than in males. The rapid onset of liver pathologies was dependent on overexpression of the transgene since it was not detected in noninduced transgenic animals of the same age. The PML-RARa protein was always present in altered tissues at much higher levels than in the surrounding normal liver tissues. In addition, overexpression of PMLRARa resulted in a strong proliferative response in the hepatocytes. We conclude that overexpression of PMLRARa deregulates cell proliferation and can induce tumorigenic changes in vivo.
Introduction
Acute promyelocytic leukemia (APL), comprising nearly 10% of the acute myeloblastic leukemia in adults, is characterized by a dierentiation block at the promyelocytic stage and a particular sensitivity to retinoic acid (RA) (for review see Warrell et al., 1993; Lavau and Dejean, 1994; Grignani et al., 1994) . Indeed treatment of APL patients with RA leads to morphological complete remissions by inducing the promyelocytic blasts to terminally dierentiate into mature granulocytes (Castaigne et al., 1990; Huang et al., 1988) . APL is associated with a consistent t(15;17) translocation that fuses the promyelocytic leukemia (PML) gene to the retinoic acid receptor a (RARa) gene (De TheÂ et al., 1991; Kakizuka et al., 1991; Goddard et al., 1991; Pandol® et al., 1991; Kastner et al., 1992) . The resulting PML-RARa hybrid protein is likely to play a crucial role in the oncogenic process, since the RARa-PML product of the reciprocal event is not systematically present in APL patients (Alcalay et al., 1992) .
The mechanism of action of the PML-RARa protein, as well as the therapeutic eect of RA on the disease are yet to be resolved. It is likely that the chimera may interfere with the normal function of either or both of the parental PML and RARa proteins. Several lines of evidence suggest that RARa, a member of the nuclear receptor multigene family (Mangelsdorf et al., 1995b; Kastner et al., 1995) , plays an important role in myeloid dierentiation (Tsai and Collins, 1993; Tsai et al., 1994) . Supporting the idea that an altered RARa is directly involved in APL pathogenesis is the ®nding that two variant translocations, t(11;17) and t(5;17), were shown to fuse the PLZF and the NPM proteins to RARa respectively (Chen et al., 1993; Redner et al., 1996) .
The biological properties of PML are still unknown. It belongs to a novel family of proteins, the RBCC family (Le Douarin et al., 1995) , sharing distinct zincbinding motifs and a coiled coil domain (Reddy et al., 1992; Borden and Freemont, 1996) . The PML gene product concentrates within discrete subnuclear structures, the so-called PML nuclear bodies, which are disrupted in an RA-reversible manner in APL cells (Weis et al., 1994; Dyck et al., 1994; Koken et al., 1994) . This suggests that the therapeutic eect of RA in APL might be related to its ability to restore a normal subnuclear organization. Little is known concerning the function of the PML nuclear bodies in normal cells. We and others have recently shown that these structures represent speci®c targets for in¯ammation, cell proliferation (Terris et al., 1995; Koken et al., 1995; Mu et al., 1994) and viral infections (Carvalho et al., 1995; Doucas et al., 1996; Everett and Maul, 1994; Kelly et al., 1995) indicating their possible involvement in distinct pathological situations.
When compared to RARa, the PML-RARa hybrid exhibits altered transactivating properties, depending on both promoter and cell types (De TheÂ , et al., 1991; Kakizuka, et al., 1991; Kastner, et al., 1992) . In contrast to RARa that requires the retinoid X receptor dimerization partner to eciently bind DNA (Mangelsdorf and Evans, 1995a), PML-RARa can bind target sequences as a homodimer with distinct DNAbinding properties suggesting that it may interfere with other nuclear receptor pathways (Perez et al., 1993; Jansen et al., 1995) . In this regard, it has been shown that the fusion protein is able to block the vitamin D3-induced dierentiation of U937 cells (Grignani et al., 1993) .
To explore the pathological consequences of PMLRARa expression in vivo, we have generated transgenic mice bearing the fusion cDNA placed under the control of the zinc-inducible metallothionein promoter. Among the 15 PML-RARa transgenic mice lines obtained, only one showed a tight control of the transgene with virtually no expression under physiological conditions and high levels of liver-restricted PMLRARa expression following zinc stimulation. This strictly inducible mouse line was thus considered for further analysis. Soon after zinc stimulation, 50% of the transgenic animals developed hepatic lesions of varying severity, ranging from foci of basophilic hepatocytes, dysplasia and hepatocellular carcinoma. Moreover, expression of the hybrid protein resulted in an abnormal liver cell proliferation. Thus, PML-RARa displays characteristics of both a potent cellular mitogen and an oncogenic protein in vivo.
Results

Generation of transgenic mice
We constructed a recombinant plasmid, MT-PMLRARa, that places the PML-RARa type L cDNA (De TheÂ , et al., 1991) under the control of the mouse metallothionein promoter (Stuart, et al., 1984) (Figure  1a ). This strategy was based on previous ®ndings that the same promoter can drive the expression of the BCR-ABL protein in the myeloid cell compartment of transgenic mice leading to the development of leukemia (Heisterkamp et al., 1990) . In addition, this promoter, which can be considered as`housekeeping' as it promotes expression in nearly all tissues in transgenic mice, is inducible by heavy metals (Palmiter et al., 1993) . This oered the possibility of generating an increased level of expression postnatally in the event that selection against constitutive PML-RARa overexpression in utero would result in mice with a particularly low basal level of expression. The MT-PML-RARa transgene was microinjected into pronuclei of fertilized eggs. Of 189 mice that developed to term, 15 had integrated one to 20 copies of the transgene (data not shown). This represents an unusually low percentage of transgenic mice when compared to what is routinely obtained with other types of constructs. Two lines did not transmit the transgene, three gave no progeny while stable transgenic lines could be established for the remaining 10 lines. 
Expression of PML-RARa in the inducible MT135 line
Kidney, spleen, liver, heart, brain, testis, ovary and bone marrow tissues from osprings of the 10 founder mice lines were analysed for expression of the transgene by Northern blot. We were not able to detect any PML-RARa transcripts in these tissues under normal conditions ( Figure 1b and data not shown). However, when mice were provided with ZnSO 4 in drinking water for 2 weeks prior to tissue collection, one line, MT135, showed a strong liverspeci®c induction of one major PML-RARa mRNA species of the expected 3.7 kb size ( Figure 1b) . None of the animals from the other nine lines showed any detectable expression of the transgene in the dierent tissues analysed including liver after zinc stimulation. Western blotting con®rmed that zinc-induced livers from MT135 males and females contained the expected 110 kd PML-RARa protein (Figure 2a) . A weak expression of the fusion protein was also noted in the brain of the male littermates (Figure 2a ). In accordance with previous ®ndings (R Palmiter, personal communication) , the analysis of the kinetics of PML-RARa expression in the liver of MT135 mice upon continuous zinc exposure revealed that the induction reached a maximum after 2 days stimulation and then progressively decreased until day 30 after which no more PML-RARa protein could be detected (Figure 2b ). We thus selected the MT135 line for further study and a 5 day treatment as the optimal timepoint for the analysis of transgene in¯uence on liver tissue structure.
Inducible liver pathologies in MT135 mice
A total of 54 2-to 6-month-old MT135 transgenic mice were analysed along with 46 nontransgenic littermates of the same age for the presence of any alteration in the liver. All animals had been administered zinc for 5 days prior to examination. While all but one of the control animals displayed a normal liver histology, 50% (27/54) of the transgenic mice showed de®ned phenotypes of preneoplastic and neoplastic lesions (Table 1) . A notable sex-related dierence was observed with a three times higher incidence of lesions among females than males (74% of females vs 26% of males developed liver alterations). Moreover, females exhibited the most severe phenotypes. Therefore protective factors in male mice and/or predisposing factors in female MT135 mice might in¯uence the neoplastic process. Cytomorphological analysis revealed three types of hepatic lesions corresponding to successive stages of the neoplastic process (Weber and Bannash, 1994) . The ®rst group (9 animals) was characterized by large populations of altered hepatocytes composed predominantly of small densely packed basophilic cells with round nuclei (Figure 3a) . Single apoptotic hepatocytes as well as in¯ammatory cells were found at the periphery of the basophilic foci.
Proliferating oval cells that expanded into the liver parenchyma along terminal branches of portal veins were also present (not shown). These alterations are phenotypically similar to those described as preneoplastic foci elicited by chemical carcinogens or viruses in rodents (Weber and Bannash, 1994; Toshkov et al., 1990; Factor and Radaeva, 1993) . In the second group (12 animals), the livers displayed mild to severe dysplasia composed of altered hepatocytes exhibiting enlarged atypical nuclei and dystrophic cytoplasms (Figure 3b,c) . The third group (6 animals) was characterized by the presence of foci of tumorous hepatocytes diagnosed as early hepatocellular carcinomas (Figure 3d ). In two animals, the tumor was composed of atypical trabecular or solid formations of clear cells. In the remaining four cases, the liver architecture was largely preserved, indicating that the progression towards the tumorous stage arose very recently. The observation, on a single liver section, of the three types of lesions (basophilic foci, dysplasia and carcinoma, Figure 3e ) is highly suggestive of the existence of a`®liation' between these dierent stages of the carcinogenic process.
The rate of hepatic alterations in MT135 mice was much higher after zinc treatment. Indeed, among 21 2-week-to 18-month-old transgenic animals which had never been treated by zinc, only three showed hepatic pathologies at 12 ± 18 months of age diagnosed as two low grade dysplasias and one carcinoma (not shown). These observations indicate that the rapid development of liver lesions in the ®rst 6 months of life is clearly correlated with the overexpression of the PML-RARa hybrid protein. Since the MT promoter is active during embryogenesis (Palmiter et al., 1982) , we were interested in studying the in¯uence of the transgene in neonatal livers. Among 20 2-week-old MT135 mice maintained with zinc since conception, 12 exhibited foci of basophilic hepatocytes (Table 1) . The susceptibility of young animals to the eect of the transgene is thus comparable to that of adult mice, however the changes induced in the neonatal liver appear to be restricted to the early stages of preneoplastic transformation. On the histological level, the unaected neonatal hepatic tissues surrounding the basophilic foci showed a preserved structure suggesting that overexpression of the PML-RARa protein during embryogenesis does not aect the normal development of the liver.
Immunohistochemical examination of peroxidase stained frozen tissue sections showed that the nuclear expression of the PML-RARa protein was systematically expressed in preneoplastic and neoplastic lesions at levels higher than those found in the surrounding unaected tissues (Figure 4 and not shown). This suggests that liver carcinogenesis involves the selection of cells capable of expressing the transgene in a strong fashion and that PML-RARa plays an active role in the tumorigenic process.
Increased cell proliferation in transgenic livers at preneoplastic stages
The rapidity with which foci of altered hepatocytes occurred in induced livers prompted us to evaluate cell proliferation from this type of lesions. Figure 5 illustrates a representative ®eld containing BrdU-labeled hepatocytes from livers of 10-week-old MT135 transgenic mice (b) and nontransgenic littermates (a). The two groups of mice had been treated with zinc for 5 days before liver resection. The fraction of BrdU-labeled S-phase hepatocytes was eightfold higher in transgenic mice than in control mice (mean values: 4+0.9% vs 0.5+0.1%). In contrast, we noted no signi®cant dierences in the rate of hepatocyte apoptosis as measured by the TUNEL method (Gavriely et al., 1992) in the transgenic animals compared to their nontransgenic littermates (not shown). These results indicate that PML-RARa induces a strong hepatocellular proliferation concomitant to liver injury.
Discussion
To date, attempts to transduce PML-RARa into murine cells using retroviral transfer techniques have failed, mainly due to the high toxicity of the fusion protein in retrovirus-producing ®broblasts . In the chicken model system, we have recently shown that PML-RARa can eciently transform hematopoietic progenitor cells in vitro and is highly leukemogenic in vivo. However, two point mutations occurred in the hybrid cDNA during the transformation process, the biological signi®cance of which remains to be clari®ed (Altabef et al., 1996) . We report here inducible liver pathologies in transgenic mice expressing the PMLRARa protein driven by the mouse MT promoter. This promoter had been previously shown to eciently direct transgene expression in a wide variety of murine tissues as well as to be inducible by heavy metals (Heisterkamp et al., 1990; Palmiter et al., 1983 Palmiter et al., , 1985 Crenshaw et al., 1987; Jhappan et al., 1990; Sandgren et al., 1990) . Nine of the 10 founder mice lines resulting from MT-PMLRARa transgene injection were considered as nonexpressors. Animals from these lines were examined for 2 years and developed no particular phenotype when compared to their nontransgenic littermates. In the remaining MT135 line, a strong hepatic expression of PML-RARa was transiently turned on following zinc stimulation. This extremely low percentage of producing founder lines argues in favor of a strong selection against PML-RARa expression leading to the generation of mice that most likely harbor transgene integration within silent genomic loci. When MT135 animals were stimulated by zinc since conception, the fetal livers developed normally, although the presence of foci of basophilic hepatocytes was readily detectable. This suggests that the liver is not a sensitive fetal tissue for the presumed lethal (cytotoxic) eect of PML-RARa.
The rapid onset of hepatic preneoplasia and neoplasia in the tightly regulated MT135 line is highly correlated with overexpression of the PML-RARa protein in the liver. While 50% of up to 6-month-old MT135 animals induced by zinc showed hepatic lesions, none of their noninduced transgenic littermates developed any alterations at a similar age. (6100) Furthermore, we found that the induction of PMLRARa expression for about 5 days was sucient to trigger cytomorphological changes in the liver, as well as a strong proliferative response. These results constitute the ®rst report establishing an active role for the PML-RARa protein in the development of preneoplasia and neoplasia in mice. The rapid emergence of liver pathologies, progressing from foci of basophilic hepatocytes through dysplasia to hepatocellular carcinoma in zinc-stimulated MT135 mice is intriguing considering the fact that the evolution of hepatic neoplasia is usually described as a slow process in rodents (Weber and Bannash, 1994; Toshkov et al., 1990; Huang and Chisari, 1995) . It is possible that a low, nondetectable expression of PMLRARa may actually exist in the livers of noninduced MT135 animals and that the increase in transgene expression by zinc treatment might therefore result in a dramatic acceleration of preneoplastic and neoplastic transformation of already`primed' hepatocytes. The ®nding of hepatic lesions, including one carcinoma, in the three oldest noninduced MT135 female mice supports this hypothesis, however analysis of a larger number of such nonstimulated transgenic animals will be necessary to clarify this issue.
The present study indicates that the liver is a highly susceptible target organ for the eect of the leukemogenic PML-RARa protein. Although the hybrid protein was present also in the brain of the induced MT135 males, we could not detect any speci®c alteration in this tissue. However we can not exclude the possibility that, in this case, this might be due to the lower level of trangene expression. The ®nding that the liver represents a possible target for oncogenic versions of the retinoic acid receptors is not unprecedented. We had previously reported hepatic pathologies in chicken infected by retroviruses transducing an hepatitis B virus-retinoic acid receptor b (HBV-RARb) hybrid protein (Dejean et al., 1986; Garcia et al., 1993) . It is interesting to note that the same HBV-RARb chimera was able to transform hematopoietic progenitor cells in vitro. It may not be coincidental that the PML-RARa and HBV-RARb proteins exhibit comparable transforming properties in two tissues (liver and bone marrow) which are both involved in hematopoiesis. The PML-RARa protein is likely to act through a blockage of dierentiation at the promyelocytic stage in APL. What could be the role of PML-RARa in the hepatocarcinogenic process in transgenic mice at the cellular level? There is increasing evidence that oval cells which appear early in the liver of rodents exposed to chemical carcinogens or viral oncogenes behave like liver stem cells with potential to dierentiate into normal as well as neoplastic hepatocytes (Factor and Radaeva, 1993; Bennoun et al., 1993) . An abnormally high number of these oval cells were found in the hepatic preneoplastic foci of the induced MT135 mice suggesting that oval cells may represent a preferential cellular target for PML-RARa action in liver. Preliminary experiments suggest that retinoic acid administration in combination with zinc stimulation does not prevent the emergence of hepatic pathologies in MT135 mice (not shown), suggesting that, unlike APL blasts which dierentiate upon RA treatment, the murine preneoplastic and neoplastic hepatocytes are apparently insensitive to the eect of retinoids. The establishment of a stable cell-line derived from a hepatocellular carcinoma induced in a MT135 mouse should be of interest to study the mechanisms of action of PMLRARa in terms of oncogenicity and RA sensitivity when compared to similar properties in the APLderived NB4 cells (Lanotte et al., 1991) .
Materials and methods
Generation of PML-RARa transgenic mice
To generate the MT-PML-RARa construct, a 250 bp fragment of the mouse metallothionein promoter, nucleotides 7185 to +65, (Stuart et al., 1984) was joined to the 4.6 kb PML-RARa type L cDNA (De TheÂ et al., 1991a) including the RARa 3' untranslated region and the two presumed polyadenylation signals (GigueÁ re et al., 1987) . The transgene was microinjected into pronuclei of fertilized (C57BL/66SJL/J) F2 hybrid eggs. Tail DNA from mice derived from injected eggs was analysed by Southern blotting. Transgenic strains were established by breeding primary transgenic animals with normal C57B1/6 mice. The male 135, which harbors six tandem copies of the transgene integrated at a single site, served as the founder animal for the MT135 line that we have studied more comprehensively. When appropriate, mice were administered 25 mM ZnSO 4 in drinking water.
Nucleic acid and protein analysis
For Southern blot analysis, 10 to 20 mg of genomic DNA was digested with PvuII, separated on a 1.2% agarose gel and transferred to nylon membrane (Hybond N+, Amersham) in 0.4 N NaOH. Hybridization was carried out according to the method of Church and Gilbert (1984) using a 902 bp PvuII fragment encompassing the translocation breakpoint in the PML-RARa cDNA (De TheÂ et al., 1991a) labeled by random priming. RNA samples were prepared from adult tissues by Polytron homogenization extracted by the single-step guanidine/isothiocyanate method (RNAzol, Cinna/biotecx Laboratories) followed by isopropanol precipitation. For Northern blot analysis, total RNA (20 mg) was size-fractionated on 1% agarose-2.2 M formaldehyde gels and transferred to Hybond-N membrane (Amersham) by blotting. Hybridization was performed as described above. Proteins were extracted from neonate and adult tissues by Polytron homogenization in lysis buer. Fifty mg of soluble protein was fractionated on a 10% SDS-polyacrylamide gel by electrophoresis. Proteins were transferred to nitrocellulose (Hybond C-extra, Amersham) by standard semi-dry electroblotting techniques. The membrane was blocked with 5% milk in PBS for 1 h, and incubated with an anti-PML antibody (Weis et al., 1994) diluted 1:200 overnight, followed by peroxidase labeled goat-antirabbit IgG. Peroxidase activity was revealed using chemiluminescent detection (ECL, Amersham).
The nucleotide sequence of the RT ± PCR product of the 3.7 kb MT-PML-RARa mRNA present in the liver of the induced MT135-56 mouse was determined using the Sequenase 2.0 DNA sequencing kit (USB, Amersham). It revealed no mutation when compared to the original sequence (De TheÂ et al., 1991a ) (data not shown).
Liver examination and immunohistochemistry
Mice were sacri®ced and tissues were ®xed in 4% formaldehyde in PBS. Fixed specimens were embedded in paran, sectioned, and stained with hematoxylin and eosin for cytomorphological examination. In parallel, a specimen of each case was frozen for immunohistochemistry. Immunostaining with a rabbit anti-PML antiserum (Weis et al., 1994) was performed on frozen sectons (5 mm) as previously described (Terris et al., 1995) .
In vivo labeling of S-phase hepatocytes 5-bromo-2'-deoxyuridine (BrdU, Sigma Chemical Co) was dissolved in PBS and injected intraperitoneally 2 h before sacri®ce at a dose of 100 mg/kg. At sacri®ce, liver lobes were ®xed in 4% paraformaldehyde, then in ethanolamine 0.1 M pH 7.4 and embedded in paran. Five mm thick sections were treated with 3% hydrogen peroxide for 30 min and then digested with 0.1% trypsin in 0.2 M Tris/HCl pH 8 for 10 min at 378C. A mouse antibody against BrdU (IgG, Pharmingen, San Deigo, CA) was applied at 1 mg/ml for 2 h. Detection was performed with the Large Volume DAKO LSAB kit (Dako, Carpinteria, CA) according to the manufacturer's instructions. Cell nuclei were counterstained with hematoxylin.
Abbreviations APL, acute promyelocytic leukemia; RA, retinoic acid.
